BOSTON, May 26, 2020 /PRNewswire/ -- Stealth
BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of novel therapies for diseases involving mitochondrial
dysfunction, today announced that Reenie
McCarthy, CEO, will participate in a fireside chat at the
Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:30
p.m. ET.
A live audio webcast of the event will be available on the
Investors & News section of Stealth's website
at https://investor.stealthbt.com/. A replay of the webcast
will be archived on Stealth's website for 30 days following the
event.
About Stealth
We are a clinical-stage biotechnology company focused on the
discovery, development and commercialization of novel therapies for
diseases involving mitochondrial dysfunction. Mitochondria, found
in nearly every cell in the body, are the body's main source of
energy production and are critical for normal organ function.
Dysfunctional mitochondria characterize a number of rare genetic
diseases and are involved in many common age-related diseases,
typically involving organ systems with high energy demands such as
the heart, the eye, and the brain. We believe our lead product
candidate, elamipretide, has the potential to treat both rare
metabolic cardiomyopathies, such as Barth, Duchenne and Becker
muscular dystrophies and Friedreich's ataxia, as well as ophthalmic
diseases entailing mitochondrial dysfunction, such as dry
age-related macular degeneration and Leber's hereditary optic
neuropathy. We are evaluating our second-generation clinical stage
candidate, SBT-272, for rare neurodegenerative disease indications
following promising preclinical data in amyotrophic lateral
sclerosis, or ALS. We have optimized our discovery platform to
identify novel mitochondria-targeted compounds, including SBT-259,
the SBT-550 series of compounds, and other compounds which may be
nominated as therapeutic product candidates or utilized as
scaffolds to deliver other compounds to mitochondria.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-present-at-jefferies-virtual-healthcare-conference-301065522.html
SOURCE Stealth BioTherapeutics Inc.